Diaveridine (DVD) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a diaminopyrimidine derivative, CAS 5355-16-8, molecular formula C13H16N4O2 and molecular weight 260.29 g/mol. The compound is manufactured as a white to off-white crystalline powder and functions as an inhibitor of dihydrofolate reductase in susceptible protozoa and bacteria. In potentiated sulfonamide systems, diaveridine acts after sulfonamide inhibition of dihydropteroate synthase, producing sequential blockade of folate biosynthesis. The molecule is chemically defined as 5-[(3,4-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine. Diaveridine is used primarily in veterinary coccidiosis control and in antibacterial combinations administered as tablets, injections, capsules, powders, granules, premixes, and oral solutions. No harmonized monograph for diaveridine currently appears in USP–NF or Ph. Eur.; therefore, release specifications are derived from manufacturer dossiers, VICH GMP requirements, and ICH Q2(R1) method-validation data.

What Physicochemical Parameters Govern Diaveridine Dispersion in Multi-Component Premixes?

Diaveridine exhibits pH-dependent solubility consistent with protonation of the pyrimidine amine groups at low pH. Published data for this specific configuration is limited; therefore, dissolution testing in compendial media at pH 1.2, pH 4.5, and pH 6.8 should be performed for each lot when the API is intended for immediate-release tablets or oral powders. The presence of the two methoxy groups on the benzyl ring reduces aqueous solubility relative to sulfonamide salts, which affects wetting and dissolution in feed and drinking water. The particle size distribution of the API must be controlled when the finished dose is below 5 mg per tablet or capsule. A D90 above 150 µm has been associated with segregation in direct compression blends and with content uniformity failures under USP 905 unless a glidant such as colloidal silicon dioxide at 0.5–1.0% w/w is used. For premix and granule operations, diaveridine is typically milled to a D90 of 100–150 µm and then blended with a carrier such as lactose monohydrate or corncob meal in a ribbon blender or V-blender. The final blend is sampled at designated intervals to verify relative standard deviation below 5.0% by HPLC assay. If the API is micronized to a D90 below 30 µm, flowability decreases and electrostatic adhesion becomes measurable, which may require wet granulation or the addition of a hydrophobized silica.

In tablet manufacture, low-dose drug loading imposes stricter control than high-dose premix application. A wet granulation step using a high-shear granulator or fluid-bed granulator is preferred when direct compression cannot maintain homogeneity. Granulation fluid is typically purified water or a binder solution of povidone at 2–5% w/w, and the dried granulate is passed through a mill fitted with a 0.8–1.2 mm screen before lubrication. Over-lubrication with magnesium stearate above 1.5% w/w has been observed to reduce tablet tensile strength and prolong disintegration time beyond compendial limits for immediate-release solid dosage forms. Tablets for veterinary oral administration are assayed for diaveridine content using reverse-phase HPLC with a C18 column, acetonitrile-phosphate buffer mobile phase, and UV detection at 230–280 nm. The method should be validated for linearity, accuracy, precision, and specificity according to ICH Q2(R1). Content uniformity and dissolution data are generated on each production lot using USP 711 apparatus II at 50 rpm with 900 mL of pH 6.8 phosphate buffer unless a different medium is justified by solubility data.

For sterile injection and oral solution presentations, the particle size and crystal habit of diaveridine require additional processing controls. Parenteral-grade diaveridine is commonly dissolved with pH adjustment using dilute hydrochloric acid or methanesulfonic acid to a final pH between 2.5 and 4.0 if aqueous solubility is sufficient. Where solubility is insufficient, co-solvent systems composed of propylene glycol, ethanol, or glycofurol are evaluated for precipitation upon dilution with serum or infusion fluids. Sterile filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane is performed before aseptic filling, and terminal sterilization at 121 °C for 15 min is used only when thermal stability data permit. Bacterial endotoxin limits for injectable diaveridine solutions are commonly set at 0.5 EU/mg or tighter, depending on the maximum dose volume and species; particulate matter is evaluated according to USP 788. Non-sterile powder intended for premix use is not automatically appropriate for parenteral administration without additional purification and endotoxin control.

Comparative Structural and Pharmacokinetic Boundaries Against Trimethoprim

The absence of the methoxy group at the 5-position of the benzyl ring in diaveridine influences retention on octadecyl silica columns, protonation equilibria, and tissue distribution relative to trimethoprim. In high-performance liquid chromatography, diaveridine generally elutes earlier than trimethoprim under isocratic acetonitrile-phosphate conditions, and the method must be optimized to separate diaveridine from sulfonamide-related substances. Pharmacokinetic differences affect product design: diaveridine is used predominantly in veterinary coccidiosis control and potentiated sulfonamide therapy, whereas trimethoprim appears in both human and veterinary formularies. The differential DHFR inhibitory potency of diaveridine against protozoal and bacterial enzymes should be confirmed by checkerboard assays using the target pathogen; published data for specific field isolates are limited. Therefore, a formulation ratio established for trimethoprim-sulfamethoxazole cannot be automatically transferred to diaveridine-sulfonamide combinations without fractional inhibitory concentration and pharmacokinetic modelling data.

Product grade differentiation is based on residual endotoxin burden, particle size, and residual solvent profile rather than on a single chemical identity. The same chemical lot is not automatically acceptable across all dosage forms. An oral premix grade may not meet the endotoxin limit required for injection; conversely, a sterile injection grade may be uneconomical for feed premix but imposes no chemical disadvantage. The product model is accordingly supplied as a low-micron crystalline powder for oral solid dosage forms and as an endotoxin-controlled powder for solution or injection manufacture.

When Diaveridine Is Wet-Granulated with Sulfonamides, What Limits Potency Recovery?

Diaveridine is chemically stable in dry blends stored at 25 °C and 60% RH for up to 24 months when protected from light, but processing conditions can create localised degradation if moisture, heat, and acidic excipients are combined. Wet granulation of a diaveridine-sulfonamide blend should avoid prolonged exposure to aqueous binder solutions above 60 °C. If a fluid-bed dryer is used, inlet air temperature should be maintained below 70 °C and product temperature below 45 °C until loss-on-drying is within specification. HPLC-related-substance analysis of stressed batches has shown increased polar degradation products when the granulation slurry is held for more than 4 h at room temperature; the exact degradation pathway is not fully described in public literature, so each granulation process should be confirmed by mass-balance and peak-purity measurements. The use of strongly alkaline or amine-based granulation agents is not recommended because diaveridine may undergo base-catalysed hydrolysis of the pyrimidine ring under certain conditions. For feed premixes, the API is typically adsorbed onto a carrier with a non-ionic surfactant or mineral oil to improve adhesion to feed particles and reduce dust formation. If the oil level exceeds 2% w/w, flowability in auger-type dosing equipment may decline, and segregation of fines can occur during transport.

In medicated feed premixes, diaveridine is mixed into a carrier before blending into final feed at an inclusion rate that must be justified by the approved product literature. Feed mill data suggest that carrier particle size distribution should overlap with the API to reduce segregation: a carrier with a D50 of 300–500 µm and a span below 1.5 retains a diaveridine D90 of 150 µm more uniformly than a coarser carrier. The premix is then dispersed into final feed at 1–10 kg/tonne depending on formulation strength and target dose; regional authorization dictates the exact inclusion rate. Ribbon blenders with a working capacity of 50–70% of total volume and a mixing time of 10–15 min are typically validated using a tracer such as iron oxide or riboflavin to confirm a coefficient of variation below 5.0% for the active component. The final feed is assayed by HPLC after extraction with an aqueous acid-organic solvent mixture, and method recovery is typically between 95% and 105% for diaveridine-spiked feed samples at levels of 50–200 mg/kg.

For capsules and direct compression formulations, the bulk density and tapped density of diaveridine powder are measured according to USP 616 and Ph. Eur. 2.9.34 to ensure reproducible filling. The Carr index and Hausner ratio are calculated for each incoming lot because variability in crystal habit from the final crystallisation step can alter compressibility even when chemical assay is unchanged. A typical acceptable Hausner ratio for direct compression is below 1.25; values above 1.35 indicate that granulation or densification is required. In capsule filling, an auger dosing disc or dosator system is selected based on the flow and bulk density of the final blend, and filled capsules are sorted by weight difference below ±5.0% for uniformity. Powder for oral suspension is prepared by blending diaveridine with sweeteners, suspending agents such as xanthan gum or hydroxyethyl cellulose, and preservatives; the dry blend is reconstituted at the point of use with potable water, and the resulting suspension is shaken before administration to re-disperse settled particles.

Residual solvent levels in diaveridine are controlled because the final crystallisation may employ ethanol, acetone, or ethyl acetate. Headspace gas chromatography is used to verify that class 3 residual solvents remain below the concentration limits of ICH Q3C; typical release limits for ethanol and acetone are 5000 ppm combined, but the exact limit is process-specific. Heavy metals, arsenic, and sulfated ash are controlled under GMP to prevent accumulation in feed-animal tissues. Injections require additional control of bacterial endotoxins and sterility; a veterinary premix powder that passes chemical assay cannot automatically be repurposed for parenteral administration. The product grade selected for a given dosage form must be declared in the regulatory dossier and supported by stability data under ICH/VICH climatic zones, including accelerated studies at 40 °C and 75% RH for 6 months in closed containers.

When diaveridine is formulated for injection, the pH after reconstitution and dilution with saline must be monitored because a shift from acidic pH to neutral pH can cause precipitation of the free base if the solubility limit is exceeded. A compatibility study with diluent at 1:10 and 1:100 dilution is performed using nephelometry or visual inspection against a black-and-white background; the acceptance criterion is no visible particulate matter after 24 h at 25 °C and 2–8 °C. If a co-solvent is used, the dielectric constant of the final solution should be adjusted so that the API remains dissolved at the lowest expected storage temperature; for a diaveridine concentration of 10 mg/mL, a co-solvent level above 40% v/v may be required, but published data for this specific configuration is limited. The solution is then filtered through a 0.22 µm sterilising filter and filled into amber vials under nitrogen to reduce oxidative degradation. The final product is tested for pH, assay, related substances, sterility, bacterial endotoxins, and particulate matter according to USP 788 and Ph. Eur. 2.9.19.